Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. News
Jul 31, 2025 - globenewswire.com
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Jul 23, 2025 - globenewswire.com
Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Jul 18, 2025 - globenewswire.com
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Jun 23, 2025 - globenewswire.com
Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Lexicon Pharmaceuticals, Inc. Quantitative Score
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Lexicon Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Lexicon Pharmaceuticals, Inc. Financials
Table Compare
Compare LXRX metrics with: | |||
|---|---|---|---|
Earnings & Growth | LXRX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LXRX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LXRX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LXRX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Lexicon Pharmaceuticals, Inc. Income
Lexicon Pharmaceuticals, Inc. Balance Sheet
Lexicon Pharmaceuticals, Inc. Cash Flow
Lexicon Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Lexicon Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Dr. Michael S. Exton Ph.D. | Chief Executive Officer & Director |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior Vice President & Chief Medical Officer |
| Mr. Brian T. Crum | Senior Vice President, General Counsel & Secretary |
| Dr. Alan J. Main Ph.D. | Executive Vice President of Innovation & Chemical Sciences |
| Ms. Kristen L. Alexander | Vice President of Finance & Accounting |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Michael S. Exton Ph.D. | Chief Executive Officer & Director | 1970 | 830.55K | |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior Vice President & Chief Medical Officer | 1965 | 717.08K | |
| Mr. Brian T. Crum | Senior Vice President, General Counsel & Secretary | Male | 1973 | 616.12K |
| Dr. Alan J. Main Ph.D. | Executive Vice President of Innovation & Chemical Sciences | 1954 | 595.45K | |
| Ms. Kristen L. Alexander | Vice President of Finance & Accounting | Female | 1968 | 379.81K |
Lexicon Pharmaceuticals, Inc. Insider Trades
| Date | 1 Jun |
| Name | Gopinathan Suma |
| Role | SVP, Discovery |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 1 Jun |
| Name | Gopinathan Suma |
| Role | SVP, Discovery |
| Transaction | Disposed |
| Type | |
| Shares | 480 |
| Date | 1 Jun |
| Name | Gopinathan Suma |
| Role | SVP, Discovery |
| Transaction | Disposed |
| Type | |
| Shares | 1000 |
| Date | 1 Jun |
| Name | Gopinathan Suma |
| Role | SVP, Discovery |
| Transaction | Disposed |
| Type | |
| Shares | 2000 |
| Date | 1 Jun |
| Name | Gopinathan Suma |
| Role | SVP, Discovery |
| Transaction | Disposed |
| Type | |
| Shares | 4800 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 1 Jun | Gopinathan Suma | SVP, Discovery | Disposed | 0 | |
| 1 Jun | Gopinathan Suma | SVP, Discovery | Disposed | 480 | |
| 1 Jun | Gopinathan Suma | SVP, Discovery | Disposed | 1000 | |
| 1 Jun | Gopinathan Suma | SVP, Discovery | Disposed | 2000 | |
| 1 Jun | Gopinathan Suma | SVP, Discovery | Disposed | 4800 |